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ABSTRACT
Iodine-131 therapy is a relatively simple,  effective and economical
method of treating hyperthyroidism. Even fifty years after the
introduction of radioactive iodine, there is no concensus on the
approach for selection of the dose for treatment of hyperthyroidism.
Since the  last three decades, the approach for radioiodine therapy at
this  Inst i tute has been to treat  with low, fract ionated doses to produce
partial destruction of the thyroid gland leaving the patient sufficient
functioning gland for normal hormone production. New in vitro
diagnostic techniques including free T3,  T4  and sensitive TSH assay
have been introduced over the past decade for the diagnosis of
hyperthyroidism. Changes in the thyroid radioactive iodine uptake in
the population due to introduction of iodized salt, and the high
incidence of persistent hyperthyroidism after ‘low dose radioiodine
therapy, have prompted to go for a proportionate i&ease in the 13’1
original  dose schedules based on goitre grades.  This has led to a nominal
increase in the incidence of post therapy hypothyroidism. However,
the basic principle of low, fractionated dose therapy is still being
followed at this Institute, which appears suitable for our social and
economic condi t ions .
1. INTRODUCTION
Thyroidectomy has been the mode of treatment of thyroid goitre since time
immemorial. It was only in’the late nineteenth century that the distinction between
toxic and non-toxic goitre was,made,  when the relation between thyroidectomy and
relief of the toxic symptoms of hyperthyroidism was appreciated. Use of antithyroid
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drugs and radioiodine therapy for hyperthyroidism started almost simultaneously in
the early 1940, and it was in 1942 that Hamilton and Hertz first put forward independent
results on the use of radioiodine in hyperthyroidism’J*.  The utility of radioiodine in
the management of hyperthyroidism was considered a major breakthrough in the
medical field ushering in a new era in the uses of radioactive substances in the
management of medical disorders.,
The late Brig. SK. Mazumdar, who has been a pioneer of nuclear medicine in
India, started a thyroid clinic at the Institute of Nuclear Medicine and Allied Sciences
(INMAS) in 1961. He propagated the use of radioiodine in the management of
hyperthyroidism.almost from the very inception ofthis  thyroid clinic, and the multiple
low dose regime of radioiodine therapy in- hyperthyroidism as is being followed in
this Institute has been his brainchild.
Over the years the thyroid research activities of the-Institute have been recognised
all over the country, and the thyroid investigative techniques and tests have also
diversified and multiplied., While radioactive iodine uptake (RAIU) and its related
studies, protein bound iodine (PBI) and later T3,  T4 and thyroid-stimulating
(thyrotropic) hormone (TSH) estimation were the initial investigations carried out, a
battery of tests including estimation of free T3 and T4,  resin uptake studies, free T3
and T4 indices, serum thyroglobulin, thyroid autoantibodies, thyroid immunoglobulins,
thyrotropin releasing hormone (TRH) stimulation test, thyroid scintiscanning including
radioiodine and technetium pertechnetate scan, ultrasonography, thermography, fine
needle aspiration cytology, computerised axial tomography (CT) and NMR scanning
of the thyroid are at present being performed. Estimation of TSH by sensitive assay
techniques has been the latest addition to the armementarium of investigative
techniques being conducted at this Institute.
During the last 29 years over one lakh patients with thyroid ailments have been.
treated at this Institute and at present more than ten thousand new .patients come
here annually for management of .thyroid disorders. Of the one lakh cases,
approximately ten thousand have come for the treatment of hyperthyroidism of which
about three thousand have been treated with radioiodine at this Institute during some
stage of thier treatment,
2. IODINE DEFICIENCY  IN DELHI
Deficiency of iodine in an area is ,known  to cause endemic goitre,
Ramalingaswamy, et al in 1961, while discussing the aetiology of endemic goitre in
the Himalayas had considered Delhi as a control area3. However in 1980, Pandav, et
al in their studies found that Delhi itself had prevelance of endemic goitre4.  Thus it
can be surmised that over this period Delhi has turned from an iodine sufficient to
an iodine deficient area. In an important research programme, 25,000 school children
in the age group 5-18 years were’ surveyed.by an INMAS team of doctors, and of
these 30 per cent were found to have goitre. Based on these and other studies, Delhi
was declared endemic for goitre and the iodized salt programme was implemented
by legislation in Delhi in the mid 1980s.
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Introduction of iodized salt has direct implication on the diagnosis and
management of hyperthyroidism as discussed below.
3. MANAGEMENT OF I-IYPERTIIYROIDISM :
This can be considered broadly under two heads, namely, diagnosisand treatment.
3.1 Diagnosis
Diagnostic protocol at this Institute consists of four parts, viz. (a) clinical
evaluation, (b) estimation of thyroid hormones T,;  T4,  TSH and thyroid
autoantibodies, (c) 13i1 thyroid uptake studies, and (d) in doubtful cases or where
clinical picture does not match the above investigations, estimation of free T,,  T4 and
thyroxine index. TRH stimulation tests are also carried out.
3. I. I Clinical Evaluation
Clinical evaluation is not only to estabiish the diagnosis but also to determine
the exact dose of radioiodine to be administered to the patient in case ‘3*1therapy  is
the choice of treatment.
Clinical factors in deciding radioiodine dose include
(i) Size of the gland-higher dose is administered for larger goitres. :
(ii) Nodularity-patients with toxic nodular goitre are-given higher dose than
those with toxic diffuse goitre.
(iii) Consistency-firm or hardgland will require more dose than soft glands.
(iv) Severity of toxicity-severely toxic patients required more dose than mildly
toxic patients.
(v) Age-older age group patients require more dose than younger patients.
3.1.2 T3, T4, TSH and Autoantibodies Estimation
T3,  T4 and TSH have been estimated by radioimmunoassay (RIA) at this institute
since 1980. Estimation of TSH by RIA has its own diagnostic limitations and for the
last two years it has been estimated by the sensitive immunoradiometric assay (IRMA).
Sensitive TSH assay is extremely useful as a first line diagnostic test for evaluating
thyroid functions>6 and is routinely done by IRMA as a screening test of thyroid
function. .
Thyroglobulin and microsomal autoantibodies are known to rise in Grave’s disease
and autoimmune disorder of the thyroid’. These antibodies have been estimated in
this Institute for a decade and in a retrospective study Shankar, et al have noted that
negative autoantibody titres show prognostically significant results both In.retum of
thyroid size to normal and of thyroid to euthyroid state in Grave’s hyperthyroidism
treated with radioiodines.
368 L Rpvi Shankar et al
3. 131Z  Thyroid Uptake Studies
1311  thyroid uptake studies have a great relevance in the diagnosis and management
of thyrotoxicosis. In this test one capsule of 1311  (25-50 &i) is administered to the
patient after an overnight fast and three tests, viz. (a) thyroid uptake at 2, 4, 6, 24,
48 & 72 hours; (b) thyroid scan at 24 hours; and (c) PB r3t1,  hepatic counts and thyroid
discharge values at 48 hours are conducted.
In a study conducted in 1983 at this Institute, Prakash, et al reported a significant
increase in the thyroid iodine uptake in comparison to iodine uptake levels in 1976
and attributed this increase to iodine deficiency in Delhi’.
In 1985, before the introduction of the iodized salt programme, the following
values were considered of diagnostic importance in thyrotoxicosis’O:
(i) Peak value of uptake in thyroid reaching within 6 hours.
(ii) Thyroid discharge more than 10 per cent at 48 hours.
(iii) More than three hundred hepatic counts per 50 &i per minute.
(iv) PB 13’1 more than 0.1 per cent per litre.
Increase in dietary iodine is known to decrease the iodine uptake in the thyroid”>‘*.
Since the introduction of iodized salt in Delhi in 1986 the uptake levels have been
decreasing and in 1988, Shankar, et al reported a marked change in the thyroid iodine
uptake in hyperthyroid individuals in comparison to the studies conducted13  in 1985.
The thyroid uptake values are uniformly reduced and there was considerable delay
in peak thyroid uptake time with reduction in the hepatic counts and thyroid discharge
values. Based on these findings, the following parameters for diagnosis of
hyperthyroidism based on 1311  uptake and related studies14  have been formulated.
(i) More than 10 per cent RAIU at 2 hours.
(ii) More than 20 per cent RAW  at 4 hours.
(iii) More than 30 per cent RAIU at 6 hours.
(iv) More than 40 per cent RAJU at 24 hours.
(v) Peak RAIU within 24 hours.
(vi) More than 2 per cent discharge at 48 hours.
(vii) More than 150 hepatic counts per 50 &i radioiodine per minute.
3.2 Treatment
Treatment of, hyperthyroidism can be broadly grouped under two heads, medical
and surgical. Medical treatment can be further subdivided into antithyroid drug
treatment and radioiodine therapy.
’ Various dosage schedules of radioiodine have been advocated for the treatment
of hyperthyroidism. No two clinics in the world would probably be following the same
type of dosage schedule. These various regimes include administering of one large
dose of radioiodine with the intention of ablating the thyroid, variable dosage method
depending on the size of the gland and severity of thyrotoxicosis, and multiple small
fractionated dose regimes15-18.
4 Radioiodine Therapy for Hyperthyroidism, 369
In the large dose regimen about 160 microcurie/g of estimated thyroid weight is
given to the patient leading to a hypothyroid state which is then followed by thyroxine
replacement therapy. This mode of treatment, although inexpensive and offering a
rapid cure to the patient, has the disadvantage of curing one disorder by knowingly
inducing another.
In a developing country like India, it is economically not possible to maintain a
patient on a life long replacement therapy. At this Institute, since its very inception,
hyperthyroidism has been treated with small doses of radioiodine with the aim of
minimising the risk of post-therapy hypothyroidism.
Though the aim has remained the same, the criteria and dosage amounts have
varied over the years. This is because an analysis of patients treated till mid 1970s
revealed that 15 per cent of patients remained persistently hyperthyroid even after
two years radioiodine therapy and they required 3-5 years to become euthyroid.
Thus, as can be seen in Table 1, the dosage schedule was modified keeping the
upper limit of radioiodine administered to a patient fixed at 5 mCi, but by increasing
the dosage for various grades of goitre. The various criteria required for calculating
dosage of radioiodine to be administered have already been mentioned.
Table 1. RdoMine  treatment seheduie  in two regimes
Dose in mCi
Gland size 1971-75 197548
Not palpable l-1.5 l - 2
Grade I 1.5-2 2 - 3
Grade II 2 - 3 3 - 4
Grade III 3 - 5 3.5-s
Grade IV 4 - s 4 - 5
With the uptake of iodine markedly reducing after the introduction of iodized
salt in the market, the dosage schedule was again modified in 1988. Classifying goitre
by the WHO Stanbury Classification”, grade IV goitre were now referred for surgery
unlike in the two previous regimes, where they were treated with radio&line. Grade
III goitres were treated with radioiodine only if the patient was unwilling for surgery
or it was contraindicated. The dosage schedule which is currently being adopted since
1988 is given in Table 2.
Prior to therapy, severity of thyrotoxicosis is judged clinically and by T3, T4  and
TSH estimation and thyroid uptake studies. All patients who have been treated with
radioiodine were maintained on propranolol therapy, (unless contraindicated) after
Table 2. RadMxhe  treatmeot  sch@ule  since 1988
Gland size Dose in mCi
Grade OA 1.5-2.5
Grade OB 1.5-3.5
Grade I 2.5-4
Grade II w.5
Grade III 4 - 5
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the initial dose of radioiodine. Dose of propranolol varies from 40-120 mg per day in
divided doses depending on the severity of the disease.
Prior to 1975, repeat doses of radioiodine used to be administered at 4-6 monthly
intervals, the repeat dosage being half the first dose. This was repeated till the patient
became euthyroid. From 1975 to 1988, between l-2 mCi radioiodine used to be given
at 2-4 monthly intervals after the initial dose depending on the clinical condition of
the patient, till euthyroid state was achieved. Since 1988, patients are being
‘re-evaluated and the same dosage of radioiodine as given in Table 2 is administered
at 2-4 monthly intervals, till the patient is euthyroid. T3 and T4 estimation is done on
each visit to confirm thyroid status.
In a comparative cumulative recovery rate study, it has been seen that in the
initial two regimes, 66 per cent of the patients recovered in one year. In the latest
regime since 1988, 85 per cent of the patients became euthyroid state in the same
period. In the regime between 1961 and 1975,15 per cent of the cases took 3-5 years
to recover whereas 95 per cent of the cases in the 1975-1988 regime recovered within
two years. Nodular goitres showed slow recovery while smaller glands recovered
faster. Only two per cent of the patients treated till 1975 went into a state of permanent
hypothyroidism while 10 per cent of patients in the regime treated till 1988 became
permanently hypothyroid. Reducing the incidence of persistent hyperthyroidism by
increasing the administered dqe.  of radioiodine has its advantages, but is marginally
offset by the nominal increase f” the development of post-therapy hypothyroidism.
It can be concluded that although, due to environmental factors, the dosage
schedule .and management of hyperthyroidism with radioiodine has been modified
and altered over the years, the basic structure as,  laid down by thelate  Brig. SK.
Mazumdar will continue to be the basis for management of hyperthyroidism.
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